Inactive Instrument

CMIC HLDG

Equities

2309

JP3359000001

Delayed Japan Exchange Other stock markets 02:00:00 2024-03-27 am EDT			5-day change	1st Jan Change
2,644 ^JPY	+0.46%		-.--%	+0.08%

Mar. 28	CMIC Holdings Delisted from Tokyo Stock Exchange	MT
Mar. 05	CMIC to Delist After Shareholder Go-Ahead for Proposed Share Consolidation	MT

CMIC HOLDINGS Co., Ltd. Announces Year-End Dividend for the Year Ended September 30, 2021; Provides Year-End Dividend Guidance for the Fiscal Year Ending September 30, 2022

November 05, 2021 at 03:00 am EDT

CMIC HOLDINGS Co., Ltd. announced year-end dividend of JPY 28.50 per share for the year ended September 30, 2021 against JPY 20.00 per share paid for the same period a year ago. The company expects to pay year-end dividend of JPY 29.00 per share for the fiscal year ending September 30, 2022 against JPY 28.50 per share for the same period a year ago.

Latest news about CMIC HLDG

CMIC Holdings Delisted from Tokyo Stock Exchange	Mar. 27	MT
CMIC to Delist After Shareholder Go-Ahead for Proposed Share Consolidation	Mar. 04	MT
CMIC Holdings to Hold Shareholders Meeting to Vote on Share Consolidation and Amendment on March 4	Feb. 01	MT
Japan's small cohort of listed firms led by women	Jan. 31	RE
CMIC HOLDINGS Co., Ltd.(TSE:2309) dropped from S&P Global BMI Index	Jan. 17	CI
CMIC Holdings Finalizes Tender Offer; Delisting Underway as Sole Shareholders Change	Jan. 05	MT
SORA Corporation completed the acquisition of 55.42% CMIC HOLDINGS Co., Ltd..	Jan. 03	CI
CMIC to Distribute 45 yen per Share Surplus Dividend, Plans to Buy Back Shares	Nov. 16	MT
CMIC HOLDINGS Co., Ltd. Announces Dividend for the Year Ended September 30, 2023, Payable on December 1,2023	Nov. 15	CI
Cmic Holdings Co., Ltd. Announces Retirement of Takeshi Hamaura as Corporate Director	Nov. 07	CI
SORA Corporation made an offer to acquire 67.23% stake in CMIC HOLDINGS Co., Ltd. for ¥33.7 billion.	Nov. 06	CI
CMIC Holdings Expands PHVC Business Model with Acquisition of Hamamatsu Pharma Research	23-10-27	MT
CMIC HOLDINGS Co., Ltd. signed a contract to acquire Hamamatsu Pharma Research Inc. from Hiroyuki Takamatsu.	23-10-25	CI
CMIC Holdings Repurchases 114,000 Shares; Completes Share Buyback Mandate Approved in November 2022	23-08-14	MT
Tranche Update on CMIC HOLDINGS Co., Ltd.'s Equity Buyback Plan announced on November 8, 2022.	23-08-14	CI
CMIC HOLDINGS Co., Ltd.'s Equity Buyback announced on November 8, 2022, has closed with 652,300 shares, representing 3.77% for ¥1,199.89 million.	23-08-09	CI
Transcript : CMIC HOLDINGS Co., Ltd., Q3 2023 Earnings Call, Aug 01, 2023	23-07-31
CMIC Repurchases Shares in June	23-07-04	MT
Tranche Update on CMIC HOLDINGS Co., Ltd.'s Equity Buyback Plan announced on November 8, 2022.	23-07-03	CI
Transcript : CMIC HOLDINGS Co., Ltd., Q2 2023 Earnings Call, May 16, 2023	23-05-15
CMIC HOLDINGS Co., Ltd. Reports Earnings Results for the Half Year Ended March 31, 2023	23-04-28	CI
CMIC HOLDINGS Co., Ltd. Announces Dividend for Second Quarter Ended March 31, 2023; Provides Year-End Dividend Guidance for the Fiscal Year Ending September 30, 2023	23-04-28	CI
CMIC HOLDINGS Co., Ltd. Revises Consolidated Earnings Guidance for the Year Ended September 30, 2023	23-04-28	CI
CMIC Repurchases Shares for 98 Million Yen in March	23-04-04	MT
Tranche Update on CMIC HOLDINGS Co., Ltd.'s Equity Buyback Plan announced on November 8, 2022.	23-04-03	CI

Chart CMIC HLDG

Duration

Period

More charts

Company Profile

CMIC HOLDINGS Co., Ltd. mainly provides pharmaceutical development support services. The Contract Research Organization (CRO) segment offers monitoring, data management, pharmaceutical consulting and nonclinical services. The Contract Manufacturing Organization (CMO) segment is engaged in the entrusted manufacture of drugs for pharmaceutical companies. The Contract Sales Organization (CSO) segment is engaged in the operation and marketing support for medicinal products. The Health Care segment conducts site support institute (SMO) business, and provides health care information services. The Intellectual Property Development (IPD) segment develops and sells diagnostic products and orphan drugs.

Sector

More about the company